Czech drugmakers hampered in bringing modern pharmaceuticals to the market

11 August 2013

Members of the Association of Innovative Pharmaceutical Industry (AIFP) and the Czech Association of Pharmaceutical Companies (CAFF) have pointed out the unlawfulness of the abolition of the suspensory effect of appeals against administrative decisions, as proposed by the Ministry of Health within the planned short-term savings of drug expenditures, according to a web posting by the AIFP.

According to representatives of both associations, this step constitutes a substantial violation of the Code of Administrative Procedure, which governs the pricing and reimbursement of pharmaceuticals in the Czech Republic. The pharmaceutical companies consider the ability of the parties to the proceedings to appeal against decisions of the State Institute for Drug Control to be an instrument guaranteed by law that allows for remedying erroneous decisions made by the authority.

Prolonged pricing and reimbursement against companies’ interests

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >